Assenagon Asset Management Boosts Investment in Intra-Cellular Therapies,
January 13, 2023
Trending News ☀️
Intra-cellular Therapies Stock Fair Value – INTRA-CELLULAR ($NASDAQ:ITCI): Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that focuses on the development of treatments for neurological and psychiatric disorders. Assenagon’s decision to invest in Intra-Cellular Therapies, Inc. is based on the company’s commitment to developing treatments that target the underlying causes of neurological and psychiatric disorders. ITI’s products are designed to address the root cause of the disorder and provide sustainable relief for the patient. ITI is also committed to working closely with regulatory authorities, healthcare providers, and researchers to ensure that its products are safe, effective, and available to those who need them. This commitment has helped the company gain recognition from key players in the industry and build a strong reputation in the field of neuroscience and psychiatry.
In addition to its commitment to developing treatments for neurological and psychiatric disorders, ITI is also dedicated to improving the lives of patients by providing educational materials on these disorders. Through this effort, they hope to raise awareness and promote understanding of these conditions so that patients can better manage their health and improve their quality of life. The recent investment from Assenagon Asset Management S.A. is an important step for Intra-Cellular Therapies, Inc. as it continues to develop groundbreaking treatments for neurological and psychiatric disorders. With this support, ITI is poised to continue its mission of providing innovative therapies for neurological and psychiatric disorders, as well as promoting understanding and improving the lives of patients who suffer from these conditions.
Price History
On Thursday, Assenagon Asset Management made a notable investment in Intra-Cellular Therapies, Inc., which saw its stock open at $47.8 and close at $48.5, up by 1.7% from the previous closing price of $47.7. At the time of writing, media exposure of the company was mostly positive. Intra-Cellular Therapies, Inc. is focused on developing innovative drug candidates for the treatment of neuropsychiatric and neurological disorders. Their therapies involve targeting intracellular processes for the treatment of these disorders. The company is currently conducting clinical trials to evaluate the safety and efficacy of its drug candidates. Intra-Cellular Therapies, Inc. has developed a pipeline of potentially transformative treatments for neuropsychiatric and neurological disorders such as schizophrenia, bipolar disorder, and depression.
The company’s lead drug candidate is lumateperone, which is currently in Phase 3 clinical trials for the treatment of schizophrenia. The company also has other drug candidates in preclinical and early clinical stages for the treatment of these disorders. The company’s focus on developing innovative intracellular therapies has attracted the attention of investors like Assenagon Asset Management. Assenagon’s investment in Intra-Cellular Therapies, Inc. is expected to boost the company’s prospects in the future. With the current positive media exposure and a strong pipeline of drug candidates, Intra-Cellular Therapies, Inc. is poised to become a leader in the development of treatments for neuropsychiatric and neurological disorders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intra-cellular Therapies. More…
| Total Revenues | Net Income | Net Margin |
| 187.21 | -297.96 | -347.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intra-cellular Therapies. More…
| Operations | Investing | Financing |
| -304.18 | -127.13 | 460.89 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intra-cellular Therapies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 782 | 96.58 | 7.24 |
Key Ratios Snapshot
Some of the financial key ratios for Intra-cellular Therapies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -78.6% | – | -349.6% |
| FCF Margin | ROE | ROA |
| -162.9% | -26.8% | -24.2% |
VI Analysis – Intra-cellular Therapies Stock Fair Value
The company’s fundamentals can be monitored and evaluated using the VI App, which provides a simple overview of the company’s long-term potential. According to the VI Line, the fair value of ITI stock is currently estimated to be around $228.4, however, the current market price of the stock is only $48.5, representing a 79% discount from its true value. This indicates that the stock is heavily undervalued and could be a great investment opportunity. The company’s products are in various stages of trials and its pipeline is full of promising prospects. Moreover, ITI has an experienced management team that has been successful in delivering results in the past. All these factors make Intra-Cellular Therapies an attractive investment opportunity for investors looking for long-term gains. More…
VI Peers
The company’s lead product candidate, lumateperone, is in Phase III clinical trials for the treatment of schizophrenia. SCYNEXIS Inc, Invion Ltd, and Shuttle Pharmaceuticals Holdings Inc are all clinical stage biopharmaceutical companies that focus on the development of small molecule drugs for the treatment of neuropsychiatric disorders.
– SCYNEXIS Inc ($NASDAQ:SCYX)
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of oral and intravenous anti-infective agents to treat patients with serious and life-threatening infections. The company’s lead product, SCY-078, is a novel, first-in-class oral and intravenous agent in clinical development for the treatment of serious fungal infections. The company’s second product, SCY-123, is an oral agent in clinical development for the treatment of bacterial infections, including Clostridium difficile infection.
– Invion Ltd ($ASX:IVX)
Invion Ltd is a development stage biopharmaceutical company, which focuses on the treatment of cancer and inflammatory disease. The company was founded in 2003 and is headquartered in Brisbane, Australia.
– Shuttle Pharmaceuticals Holdings Inc ($NASDAQ:SHPH)
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 25.81M as of 2022. The company has a Return on Equity of 47.66%. Shuttle Pharmaceuticals Holdings Inc is engaged in the research, development, manufacture, and sale of pharmaceutical products. The company’s products include prescription and over-the-counter drugs, as well as nutritional supplements and other health-related products.
Summary
Intra-Cellular Therapies, Inc. is a biopharmaceutical company that is becoming increasingly attractive to investors. With the recent boost in investment from Assenagon Asset Management, the company’s stock price has seen an increase. The media has also been covering the company positively, with its potential for strong returns due to their innovative treatments and therapies.
This creates an optimistic outlook among investors, who are expecting long-term growth. With its promising pipeline of products and its well-known collaborations, Intra-Cellular Therapies is expected to provide a profitable return on investment in the near future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
